PharmaEngine, Inc. (TPEX:4162)

Taiwan · Delayed Price · Currency is TWD

58.20

+1.50 (2.65%)

Oct 30, 2026, 1:30 PM CST

Market Cap	8.36B -12.9%
Revenue (ttm)	1.03B -58.7%
Net Income	538.80M -67.0%
EPS	3.75 -66.9%
Shares Out	143.68M
PE Ratio	15.52
Forward PE	n/a
Dividend	2.00 (3.44%)
Ex-Dividend Date	Aug 17, 2026

Volume	1,018,387
Open	57.70
Previous Close	56.70
Day's Range	56.70 - 58.40
52-Week Range	53.00 - 74.40
Beta	0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 45

Stock Exchange Taipei Exchange

Ticker Symbol 4162

Full Company Profile

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.

Financial Statements